Skip to content

Study for the characteristics of peripheral blood cell biosynthesis and mitochondrial fusion and division of patient with myasthenia gravis

Study for the characteristics of peripheral blood cell biosynthesis and mitochondrial fusion and division of patient with myasthenia gravis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017903
Enrollment
Unknown
Registered
2018-08-20
Start date
2018-09-01
Completion date
Unknown
Last updated
2018-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myasthenia Gravis

Interventions

MG patients and healthy volunteers:Collect blood sample in the morning

Sponsors

Institute of Spleen-Stomach, Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
17 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients: 1. The diagnosis of MG was based on the diagnostic criteria of Practical internal science (Peoples Medical Publishing HouseThe 15th edition)and patients with MG belonging to the the modifed Osseman II type; 2. The above diagnosis is the first diagnosis; 3. Although MG is not the first diagnosis, patients have a medical history of MG and their pathogenic condition is closed to the relapse, aggravation or treatment of MG; 4. Clinical medical records are complete; 5. Aged 14 to 75 years; 6. Patients informed and willing to participate in this study. Healthy volunteers: 1. Aged 14 to 75 years; 2. No medical history of MG; 3. Volunteers informed and willing to participate in this study.

Exclusion criteria

Exclusion criteria: 1. MG is not the first diagnosis; 2. Clinical medical records are not complete; 3. The patient has other serious complications, such as mental disease, cerebrovascular disease, heart failure, liver failure, kidney failure or malignant tumor; 4. The patients with familial MG; 5. Allergy (allergic to 2 or more kinds of food or drugs); 6. Patients has participated in other clinical trials in last month; 7. the patients who received the treatment with plasma exchange or intravenous gamma globulin in the past three months

Design outcomes

Primary

MeasureTime frame
mitochondrial biogenesis and mitochondrial fusion and fission;

Countries

China

Contacts

Public ContactYafang Song

Guangzhou University of Chinese Medicine

journalemail@163.com+86 13570238612

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026